Literature DB >> 15644432

Time-dependent changes in receptor/G-protein coupling in rat brain following chronic monoamine transporter blockade.

Kerry A O'Connor1, Linda J Porrino, Huw M L Davies, Steven R Childers.   

Abstract

The potent tropane analog, WF-23 [2beta-propanoyl-3beta-(2-naphthyl) tropane], blocks dopamine, serotonin, and norepinephrine transporters with high affinity in vitro and blocks transporters for at least 2 days following a single in vivo administration. Previous studies demonstrated desensitization of monoamine receptor-coupled G-proteins in brain following chronic treatment of rats with WF-23. The current study sought to determine the time course of this desensitization and the behavioral effects of receptor desensitization. Rats were treated with 1 mg/kg WF-23 and injected i.p. every 48 h for 1 to 21 days. Receptor activation of G-proteins was determined by guanosine 5'-O-(3-[(35)S]thiotriphosphate) ([(35)S]GTPgammaS) binding in brain sections for monoamine receptors, as well as mu opioid receptors as a nonmonoamine receptor control. Chronic treatment with WF-23 produced significant reductions in D(2), 5-hydroxytryptamine 1A, and alpha(2)-adrenergic receptor-stimulated [(35)S]GTPgammaS binding; however, the time course of desensitization varied with different receptors. There was no effect of WF-23 treatment on mu opioid-stimulated [(35)S]GTPgammaS binding at any time point. Consistent with previous studies, there was no effect of WF-23 treatment on D(2) receptor binding, as determined by [(3)H]spiperone autoradiography. Locomotor activity was significantly increased for up to 48 h following acute administration of WF-23, demonstrated by increased photocell beam interruptions. WF-23-induced increases in locomotor activity occurred following repeated administration, as above, for up to 7 days. Following 7 days of treatment, there was a significant decrease in WF-23-increased locomotor activity. This reduction occurred at the same time point as the decrease in D(2) receptor/G-protein coupling, suggesting a role of D(2) desensitization in producing tolerance to WF-23-mediated behavior.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644432      PMCID: PMC4353408          DOI: 10.1124/jpet.104.078451

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone.

Authors:  L J Sim-Selley; L J Vogt; R Xiao; S R Childers; D E Selley
Journal:  Eur J Pharmacol       Date:  2000-02-18       Impact factor: 4.432

2.  Chronic repeated cocaine administration increases dopamine D1 receptor-mediated signal transduction.

Authors:  E M Unterwald; J Fillmore; M J Kreek
Journal:  Eur J Pharmacol       Date:  1996-12-27       Impact factor: 4.432

3.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine.

Authors:  M C Ritz; R J Lamb; S R Goldberg; M J Kuhar
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

4.  Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain.

Authors:  B A Bennett; C H Wichems; C K Hollingsworth; H M Davies; C Thornley; T Sexton; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  1995-03       Impact factor: 4.030

5.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

6.  Novel 2-substituted cocaine analogs: binding properties at dopamine transport sites in rat striatum.

Authors:  H M Davies; E Saikali; T Sexton; S R Childers
Journal:  Eur J Pharmacol       Date:  1993-01-04       Impact factor: 4.432

7.  Structure-activity relationships for substrate recognition by the human dopamine transporter.

Authors:  Michael Appell; Janet L Berfield; Lijuan C Wang; William J Dunn; Nianhang Chen; Maarten E A Reith
Journal:  Biochem Pharmacol       Date:  2004-01-15       Impact factor: 5.858

8.  The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics.

Authors:  Joshua A Lile; Zhixia Wang; William L Woolverton; Jessica E France; Timothy C Gregg; Huw M L Davies; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

9.  High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain.

Authors:  J W Boja; W M Mitchell; A Patel; T A Kopajtic; F I Carroll; A H Lewin; P Abraham; M J Kuhar
Journal:  Synapse       Date:  1992-09       Impact factor: 2.562

10.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding.

Authors:  L J Sim; D E Selley; S R Childers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  3 in total

1.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

2.  Inhibiting subthalamic D5 receptor constitutive activity alleviates abnormal electrical activity and reverses motor impairment in a rat model of Parkinson's disease.

Authors:  Jonathan Chetrit; Anne Taupignon; Lionel Froux; Stephanie Morin; Rabia Bouali-Benazzouz; Frédéric Naudet; Nabila Kadiri; Christian E Gross; Bernard Bioulac; Abdelhamid Benazzouz
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

3.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.